Onderzoeker
Kristof CUPPENS
- Trefwoorden:Ongekend
- Disciplines:Immunologie niet elders geclassificeerd
Affiliaties
- Immunologie & Infectie (Departement)
Lid
Vanaf1 okt 2021 → Heden - Immunologie & Infectie (Onderzoeksgroep)
Lid
Vanaf1 okt 2021 → Heden - Limburg Clinical Research Center (Onderzoekscentrum)
Lid
Vanaf1 okt 2021 → Heden - Geneeskunde en Levenswetenschappen (Faculteit)
Lid
Vanaf1 okt 2021 → Heden
Publicaties
1 - 10 van 12
- Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04(2023)
Auteurs: K. P. Papadopoulos, D. Bruno, S. Kitazono, S. Murakami, M. Gutierrez, K. Wakuda, A. Spira, Kristof CUPPENS, S. Lovick, A. Hepner, et al.
Pagina's: S55 - The path forward in early-stage lung cancer(2023)
Auteurs: Kristof CUPPENS, Paul Baas
Pagina's: 11 - 13 - Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial(2023)
Auteurs: Byoung Chul Cho, Jong Seok Lee, Yi-Long Wu, Irfan Cicin, Manuel Cobo Dols, Myung-Ju Ahn, Kristof CUPPENS, Remi Veillon, Ernest Nadal, Josiane Mourao Dias, et al.
Pagina's: 1731 - 1742 - Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancer(2023)
Auteurs: H. C. Donker, Kristof CUPPENS, Guy FROYEN, H. J. M. Groen, T. J. N. Hiltermann, Brigitte MAES, E. Schuuring, P. -J. Volders, G. A. Lunter, B. van Es
- Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications(2023)
Auteurs: Olivia Vandekerckhove, Kristof CUPPENS, Karin Pat, Bert Du Pont, Guy FROYEN, Brigitte MAES
- UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)(2023)
Auteurs: Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wolner, Ofer Rotem, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip Patel, et al.
Pagina's: 169 - 180 - Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment(2022)
Auteurs: Abed Agbarya, Walid Shalata, Alfredo Addeo, Andriani Charpidou, Kristof CUPPENS, Odd Terje Brustugun, Mirjana Rajer, Marco Jakopovic, Mihai, V Marinca, Adam Pluzanski, et al.
- A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer(2022)
Auteurs: Anne Sibille, Frederique Bustin, Luciano Carestia, Gaetan Catala, Christophe Compere, Kristof CUPPENS, Benoit Colinet, Stephanie Coulon, Nele De Brucker, Lore Decoster, et al.
Pagina's: 773 - 776 - HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors(2022)
Auteurs: Kristof CUPPENS, Paul Baas, Ellen GEERDENS, Bert Cruys, Guy FROYEN, Lynn Decoster, Michiel THOMEER, Brigitte MAES
Pagina's: 1 - 10 - Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-sma...(2022)
Auteurs: J. F. Vansteenkiste, I. Demedts, E. Pons-Tostivint, B. Biesma, F. Borm, B. Colinet, Kristof CUPPENS, S. Derijcke, L. Greillier, J. Juergens, et al.
Pagina's: S1086